GSK plc (NYSE:GSK) Shares Purchased by Buckhead Capital Management LLC

Buckhead Capital Management LLC lifted its position in GSK plc (NYSE:GSK) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,053 shares of the pharmaceutical company’s stock after acquiring an additional 762 shares during the period. GSK accounts for approximately 1.5% of Buckhead Capital Management LLC’s investment portfolio, making the stock its 28th biggest holding. Buckhead Capital Management LLC’s holdings in GSK were worth $3,967,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 676 shares during the period. Larson Financial Group LLC boosted its holdings in GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 647 shares during the last quarter. BKM Wealth Management LLC purchased a new stake in GSK in the fourth quarter valued at $32,000. Jones Financial Companies Lllp boosted its holdings in GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after purchasing an additional 509 shares during the last quarter. Finally, Princeton Global Asset Management LLC boosted its holdings in GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock valued at $56,000 after purchasing an additional 533 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GSK shares. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy”.

GSK Stock Up 2.7 %

Shares of GSK stock traded up $1.13 during trading on Wednesday, hitting $42.57. 4,256,293 shares of the stock were exchanged, compared to its average volume of 3,463,409. The stock has a market cap of $88.22 billion, a price-to-earnings ratio of 13.76, a price-to-earnings-growth ratio of 1.46 and a beta of 0.64. The firm’s 50-day moving average price is $41.81 and its 200 day moving average price is $39.04. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. As a group, analysts forecast that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were paid a dividend of $0.3564 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a yield of 3.35%. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio is currently 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.